13th Feb 2020 14:45
(Alliance News) - Drug consulting firm Open Orphan PLC on Thursday said it has promoted Leo Toole to the role of chief financial officer on a permanent basis, effective immediately.
Toole was previously interim chief financial officer of the pharmaceutical company. He also served as finance director of the Open Orphan division following the merger with hVIVO in January.
Leo Toole brings over 20 years of experience in senior finance roles in the pharmaceuticals, medical technology and FMCG sectors, the Dublin-based company said, adding that he has held senior finance positions at consumer goods manufacturer Procter & Gamble Co, US-based sleep device manufacturer ResMed and clinical stage biotechnology company Sublimity Therapeutics Ltd.
"I am delighted that we have appointed Leo as chief financial officer. He has worked with Open Orphan for the past year and is therefore well placed to assist with the rapid integration of hVIVO, deliver on our synergies programme and target profitability in the near term. We feel he is an important addition the executive team as we target the rapidly-growing CRO pharmaceutical services sector," said Executive Chair Cathal Friel.
The stock was up 0.8% at 6.000 pence each on Thursday afternoon in London.
By Ife Taiwo; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
ORPH.L